<DOC>
	<DOCNO>NCT01150877</DOCNO>
	<brief_summary>The purpose study investigate therapeutic effect safety high-dose vitamin D supplementation metastatic colorectal cancer patient . We propose supplement metastatic ( stage 4 ) colorectal cancer patient oral dos vitamin D raise serum 25-hydroxy-vitamin D [ 25 ( OH ) D ] level high normal range 200-250 nmol/L . The primary objective study evaluate metabolic consequence , include tolerability toxicity , prolong , high-dose physiological vitamin D patient colorectal cancer . The secondary objective evaluate patient survival regard high-dose vitamin D supplementation . Hypothesis : Whereas low dos vitamin D reportedly play significant role prevention colorectal cancer , much large ( pharmacological ) dose vitamin D significant therapeutic effect kind cancer ?</brief_summary>
	<brief_title>High Dose Vitamin D Study</brief_title>
	<detailed_description>Metastatic ( stage 4 ) colorectal cancer patient randomly assign treatment arm study orally supplement high dos vitamin D achieve serum 25 ( OH ) D concentration 200-250 nmol/L ( 80-100 ng/ml ) . Therefore , supplementation dosage pre-set determine individual basis . Vitamin D supplementation continue 16 month , follow 12 month follow period . Monthly monitoring serum 25 ( OH ) D calcium level assure safety treatment protocol . Subjects control arm study receive standard cancer care InspireHealth include supplementation least 2,000 International Units vitamin D .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Inclusion Criteria ( We recruit stage 4 ( metastatic ) colorectal cancer patient client InspireHealth ) : Age &gt; 18 Histologically confirm colon rectal cancer Known metastatic disease ( stage4 ) confirm histologically radiologically Life expectancy &gt; 8 month May receive antineoplastic therapy discretion physician Stable metastatic disease define change systemic month month commence study Signed informed consent Exclusion Criteria ( Stage 4 colorectal cancer patient ) : Pregnant / lactate woman Known hypersensitivity vitamin D Preexisting renal stone disease base history Preexisting hypercalcemia Severe renal hepatic dysfunction ( â‰¥ 2x upper normal range ) granulomatous disease ( TB sarcoid ) unable give inform consent English ( translation study document language English provide )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Vitamin D3</keyword>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>Cholecalciferol</keyword>
</DOC>